{"gene":"ADAMTS13","run_date":"2026-06-09T22:02:41","timeline":{"discoveries":[{"year":2001,"finding":"ADAMTS13 (VWFCP) is a 1427-amino-acid metalloprotease with a domain architecture comprising: signal peptide, short propeptide (ending in RQRR furin cleavage site), reprolysin-like metalloprotease domain, disintegrin-like domain, thrombospondin-1 repeat, Cys-rich domain, spacer domain, seven additional TSP1 repeats, and two CUB domains. The protein contains conserved Zn2+ and Ca2+ binding sites in the protease domain. Northern blotting detected full-length mRNA only in liver. The protein is apparently synthesized as a zymogen requiring proteolytic activation, possibly by furin.","method":"cDNA cloning, Northern blotting, domain architecture analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — foundational molecular cloning with functional domain characterization, replicated across multiple subsequent studies","pmids":["11557746"],"is_preprint":false},{"year":2002,"finding":"Recombinant ADAMTS13 expressed in HEK293 cells degrades VWF multimers and proteolytically cleaves VWF to the same fragments generated by plasma VWF-cleaving protease, confirming ADAMTS13 is the physiologic VWF-cleaving metalloprotease. Recombinant ADAMTS13-mediated VWF degradation was entirely inhibited by plasma from an acquired TTP patient (containing inhibitory autoantibodies).","method":"Expression of recombinant ADAMTS13 in HEK293 cells, VWF multimer degradation assay, inhibition by TTP patient plasma","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional reconstitution with recombinant protein, replicated by independent groups","pmids":["12393399"],"is_preprint":false},{"year":2002,"finding":"Missense mutations R268P and C508Y in ADAMTS13 abolish enzyme activity by preventing secretion from cells. Nonsense mutation Q449stop and missense P475S produce secreted protein with minimal or reduced activity respectively, demonstrating that defects in both protein secretion and catalytic activity are mechanisms underlying congenital TTP.","method":"Expression analysis of mutant ADAMTS13 in HeLa cells, activity assays, secretion analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure-function mutagenesis with orthogonal secretion and activity readouts, confirmed in cell culture","pmids":["12181489"],"is_preprint":false},{"year":2005,"finding":"ADAMTS13 is expressed primarily by hepatic stellate cells in the liver. In situ hybridization, cell fractionation with proteolytic activity measurement in conditioned media, and RT-PCR of isolated hepatic stellate cells all identified this cell type as the primary hepatic source. Mouse ADAMTS13 cloned from hepatic stellate cells was active against VWF and inhibited by EDTA or TTP patient IgG inhibitors.","method":"In situ hybridization, cell fractionation with activity assays, RT-PCR, cloning from primary hepatic stellate cells","journal":"Laboratory investigation; a journal of technical methods and pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ISH, fractionation with functional assay, RT-PCR) converging on same conclusion","pmids":["15806136"],"is_preprint":false},{"year":2007,"finding":"ADAMTS13 preferentially cleaves platelet-VWF complexes under fluid shear stress. Platelet-dependent cleavage was blocked by anti-GPIbalpha monoclonal antibody or soluble GPIbalpha fragment, demonstrating that platelet binding to VWF via GPIbalpha is required for this enhanced proteolysis. Shear and platelet-dependent cleavage preferentially consumed large VWF multimers.","method":"Cone-plate viscometer shear assay, blocking antibodies against GPIbalpha, multimeric gel analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional blocking experiments with antibody and recombinant fragment, multiple orthogonal methods","pmids":["17901248"],"is_preprint":false},{"year":2009,"finding":"ADAMTS13 is released constitutively from endothelial cells directly from the Golgi to the cell exterior, without storage in an organelle (unlike VWF which is stored in Weibel-Palade bodies). HUVEC-released ADAMTS13 cleaves secreted and cell-anchored VWF strings at the Y1605-M1606 bond within 15 minutes. Blocking antibodies against different ADAMTS13 domains detected ADAMTS13 attachment along the lengths of VWF strings on the endothelial surface.","method":"Live-cell imaging of HUVEC, immunofluorescence with domain-specific antibodies, VWF cleavage assay under static conditions","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiment with functional consequence (VWF string cleavage), multiple domain-specific blocking antibodies","pmids":["19822897"],"is_preprint":false},{"year":2010,"finding":"Two subsites in the ADAMTS13 metalloprotease domain are critical for function: VR1 (D187-R193) contains residues D187, R190, and R193 that influence cleavage efficiency (point mutants reduce kcat/Km 2-10 fold); VR3 residues D252-P256 influence P1' amino acid specificity, shaping the S1' substrate-binding pocket.","method":"Domain swapping between ADAMTS13 and ADAMTS1/2, site-directed mutagenesis, kinetic analysis with VWF115 substrate","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis with kinetic analysis identifying catalytic subsites","pmids":["20647566"],"is_preprint":false},{"year":2007,"finding":"N-linked glycan at position N1574 in the VWF A2 domain modulates ADAMTS13 interaction; mutation of N1574 increased VWF susceptibility to ADAMTS13 proteolysis and allowed cleavage in the absence of urea. N1515 mutation did not alter ADAMTS13 binding or proteolysis rate. ABO blood group sugars are presented on N-linked glycans at N1515 and N1574.","method":"PNGase F digestion, lectin analysis, recombinant VWF mutagenesis, binding and proteolysis assays with isolated VWF-A2 domain","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with recombinant mutant VWF, multiple orthogonal assays","pmids":["17975018"],"is_preprint":false},{"year":2014,"finding":"The distal T8-CUB2 domains of ADAMTS13 markedly inhibit substrate cleavage (autoinhibition). Binding of VWF (specifically the D4 domain) or monoclonal antibodies to distal ADAMTS13 domains relieves this autoinhibition. Small angle X-ray scattering demonstrated that distal T-CUB domains physically interact with proximal MDTCS domains in the resting state, supporting substrate-induced allosteric activation.","method":"Kinetic assays with truncated ADAMTS13 variants, SAXS, monoclonal antibody-mediated domain blocking","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — SAXS structural data combined with kinetic functional assays and mutagenesis/truncation analysis","pmids":["25512528"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of ADAMTS13 metalloprotease-to-spacer domains reveals the metalloprotease domain in a latent conformation with an occluded active-site cleft. Kinetic analyses showed that binding of the ADAMTS13 cysteine-rich and spacer domain exosites to VWF brings enzyme and substrate into proximity, then binding of the disintegrin-like domain exosite to VWF allosterically activates the adjacent metalloprotease domain by opening the active-site cleft. VWF thus functions as both the activating cofactor and substrate for ADAMTS13.","method":"X-ray crystallography, kinetic analysis, exosite mutagenesis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus kinetic functional validation in a single rigorous study","pmids":["31439947"],"is_preprint":false},{"year":2019,"finding":"T7 and T8 distal domains of ADAMTS13 are essential for allosteric activation by VWF; deletion of either T7 or T8 abolished allosteric activation. In contrast, T3-T6 domains are dispensable: pigeon ADAMTS13 with only 3 distal T domains retained normal allosteric regulation and shear-dependent VWF cleavage. Human ADAMTS13 engineered to resemble pigeon ADAMTS13 (lacking T3-T6) retained normal allosteric regulation.","method":"Phylogenetic analysis, domain deletion variants, kinetic assays across 20 mammalian/avian/amphibian species, shear-dependent cleavage assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic domain deletion with functional reconstitution across multiple species and constructs","pmids":["30700419"],"is_preprint":false},{"year":2020,"finding":"Antibody-induced conformational activation of ADAMTS13 (from closed/folded to open conformation) enhances ADAMTS13 proteolytic function by increasing kcat (turnover), not by augmenting substrate binding (Km unchanged). This mechanism is allosteric, acting on the metalloprotease domain active site, not via exposure of cysteine-rich or spacer domain exosites. Conformational extension exposes a cryptic epitope in the metalloprotease domain that is normally concealed in the closed conformation.","method":"Kinetic analysis (Km, kcat, kcat/Km), conformation ELISA, domain-specific monoclonal antibodies (anti-Spacer 3E4, anti-CUB1 17G2)","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous kinetic dissection with two orthogonal activating antibodies, mechanistic resolution of kcat vs Km","pmids":["32196558"],"is_preprint":false},{"year":2008,"finding":"ADAMTS13 catalysis of Tyr1605-Met1606 bond hydrolysis in VWF is governed by two ionizable groups (pKa 6.41 and ~4.0). The transition state has negative activation entropy, indicating an ordered transition state. The VWF Met1606-Arg1668 product acts as a hyperbolic mixed-type inhibitor. Residues Asp1653, Glu1655, Glu1660, Asp1663, and Thr1656 in VWF A2 form a 'hot spot' driving molecular recognition by ADAMTS13. A molecular model indicates ADAMTS13 must adopt a C-like shape to accommodate substrate and properly orient the scissile bond.","method":"Fluorescence quenching (FRETS) kinetic assays across temperature and pH ranges, Co2+ substitution, product inhibition analysis, molecular modeling","journal":"Biophysical journal","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous in vitro kinetic analysis but single lab, computational model not independently validated","pmids":["18502798"],"is_preprint":false},{"year":2005,"finding":"ADAMTS13 is also synthesized and secreted by vascular endothelial cells, and platelet lysates contain functionally active ADAMTS13 that cleaves endothelial cell-derived ultra-large VWF under static and flow conditions. Platelet surface ADAMTS13 expression increases upon activation by thrombin receptor-activating peptide but not ADP. The platelet-derived ADAMTS13 activity is inhibited by EDTA and by TTP patient anti-ADAMTS13 IgG.","method":"ADAMTS13 activity assay in platelet lysates, anti-ADAMTS13 antibody blocking, flow-based VWF cleavage assay, platelet activation assays","journal":"Journal of thrombosis and haemostasis : JTH","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional activity demonstrated with blocking antibodies and flow assays, single lab but multiple methods","pmids":["16176307"],"is_preprint":false},{"year":2010,"finding":"Biologically active ADAMTS13 is expressed and secreted by human renal tubular epithelial cells (primary HRTEC and A498 cell line), demonstrated by RT-PCR, immunofluorescence, immunoblotting, and proteolytic cleavage of FRETS-VWF73 substrate. ADAMTS13 was also detected in situ in proximal and distal renal tubules in normal human kidney and was present in urine of patients with tubulopathy (but not normal urine), indicating the protease originates in tubuli.","method":"Real-time PCR, immunofluorescence, immunoblotting, FRETS-VWF73 substrate cleavage assay, immunohistochemistry, urine analysis","journal":"Pediatric nephrology (Berlin, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods demonstrating expression, localization, and functional activity, single lab","pmids":["19644711"],"is_preprint":false},{"year":2011,"finding":"Human glomerular endothelial cells express, secrete, and produce functionally active ADAMTS13, demonstrated by real-time PCR, flow cytometry, immunofluorescence, immunoblotting, and VWF cleavage assays. ADAMTS13-deficient mice showed thickening of glomerular capillaries with platelet deposition on vessel walls, indicating ADAMTS13 protects against glomerular platelet deposition.","method":"RT-PCR, flow cytometry, immunofluorescence, immunoblotting, VWF cleavage assay, immunohistochemistry of Adamts13-/- vs wild-type mouse kidneys","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in cell culture plus knockout mouse phenotype, single lab","pmids":["21720563"],"is_preprint":false},{"year":2010,"finding":"Thrombospondin-1 (TSP1) competitively inhibits ADAMTS13 binding and cleavage of VWF by binding to VWF A2 and A3 domains. TSP1 partially blocked ADAMTS13 binding to A2 and A3 domains and full-length VWF, and inhibited ADAMTS13 activity by up to 70% in vitro.","method":"ELISA-based binding assay with recombinant VWF A1/A2/A3 domains, western blot, residual collagen binding assay for ADAMTS13 activity","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — competitive binding and functional inhibition demonstrated by two orthogonal assays, single lab","pmids":["20705333"],"is_preprint":false},{"year":2012,"finding":"ADAMTS13 is endocytosed by immature monocyte-derived dendritic cells via the macrophage mannose receptor (MR). Endocytosis was blocked by EGTA (Ca2+-dependent), mannan (competing mannose sugar), and an anti-MR blocking monoclonal antibody. siRNA silencing of MR reduced ADAMTS13 uptake. In vitro binding studies confirmed interaction between ADAMTS13 sugar moieties and the carbohydrate recognition domains of MR.","method":"Flow cytometry, confocal microscopy, siRNA knockdown of MR, in vitro binding assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal evidence from blocking antibody, siRNA knockdown, and direct binding assay; multiple orthogonal methods converging","pmids":["22289891"],"is_preprint":false},{"year":2012,"finding":"Recombinant ADAMTS13 promotes endothelial cell tube formation, proliferation, and migration in a dose-dependent manner. ADAMTS13 inhibits VEGF-induced angiogenesis, and this inhibitory effect is reversed by antibody against ADAMTS13 TSP1 domains 5-7. Truncated ADAMTS13 lacking the C-terminal TSP1 domain failed to stimulate angiogenesis. Co-immunoprecipitation demonstrated that ADAMTS13 binds VEGF via its TSP1 domain.","method":"Matrigel tube formation assay, proliferation counting assay, Boyden chamber migration assay, co-immunoprecipitation, domain truncation analysis","journal":"Microvascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cellular assays plus Co-IP for protein interaction, single lab","pmids":["22626948"],"is_preprint":false},{"year":2014,"finding":"ADAMTS13 modulates atherosclerotic plaque progression through a VWF-dependent mechanism. Triple knockout Adamts13-/-/Vwf-/-/ApoE-/- mice showed complete reversal of exacerbated atherosclerosis seen in Adamts13-/-/ApoE-/- mice, with lesion size, macrophage and neutrophil infiltration, and collagen content reduced to levels seen in Vwf-/-/ApoE-/- mice.","method":"Genetic epistasis using triple knockout mice, histological analysis, immunohistochemistry for macrophages and neutrophils, picrosirius red staining for collagen","journal":"Journal of thrombosis and haemostasis : JTH","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in triple knockout mice demonstrating VWF-dependency of ADAMTS13 effect on atherosclerosis","pmids":["24261607"],"is_preprint":false},{"year":2014,"finding":"ADAMTS13 TSP1 repeats (specifically TSP1 2-8) are required for its pro-angiogenic effects; variants containing TSP1 2-8 repeats increased HUVEC proliferation, migration, and VEGFR2 phosphorylation. ADAMTS13 induces VEGF expression (53% increase at protein level, >6-fold increase in mRNA) within 10 minutes. Anti-VEGF IgG abrogated ADAMTS13-enhanced proliferation, migration, and VEGFR2 phosphorylation.","method":"Structure-function analysis with ADAMTS13 truncation variants, ELISA, Western blot for VEGF and phospho-VEGFR2, proliferation and chemotaxis assays, anti-VEGF blocking","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain structure-function combined with signaling readouts and antibody blocking, single lab","pmids":["24950743"],"is_preprint":false},{"year":2007,"finding":"In endotoxemia mice, ADAMTS13 plasma activity is decreased within 2 hours of LPS injection. Pretreatment with a neutrophil elastase inhibitor or use of plasminogen-deficient mice prevented the decrease in ADAMTS13 activity, demonstrating that both plasmin and neutrophil elastase coordinately degrade/inactivate ADAMTS13 in endotoxinemia.","method":"LPS injection in mice, pharmacological neutrophil elastase inhibitor pretreatment, plasminogen-deficient mouse model, ADAMTS13 activity assays","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological epistasis identifying specific proteases responsible for ADAMTS13 inactivation, single lab","pmids":["18006046"],"is_preprint":false},{"year":2017,"finding":"ADAMTS13 deficiency impairs post-stroke neovascularization; Adamts13-/- mice showed reduced microvessels, brain capillary perfusion, pericyte coverage, and accelerated BBB breakdown after stroke. These vascular defects were reversed by VWF deficiency or anti-VWF antibody in Adamts13-/- mice. ADAMTS13 deficiency decreased angiopoietin-2 and galectin-3 in brain microvessels; VWF deficiency had the opposite effect. Recombinant ADAMTS13 treatment at 7 days post-stroke increased neovascularization and improved functional recovery.","method":"Adamts13-/- and Vwf-/- mouse stroke model, intravital microscopy, histology, recombinant ADAMTS13 treatment, adenovirus angiopoietin-2 overexpression, VEGFR2 antagonist (SU1498)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double knockout rescue), pharmacological intervention, and recombinant protein treatment with multiple orthogonal readouts","pmids":["28428179"],"is_preprint":false},{"year":2017,"finding":"ADAMTS13 is expressed in human placenta, primarily in trophoblasts and villous core fetal vessel endothelium, and is proteolytically active. Placental ADAMTS13 expression is highest in the first trimester and significantly reduced under hypoxic conditions and in preeclampsia. Recombinant ADAMTS13 stimulates proliferation, migration, invasion, and network formation of trophoblastic cells; knockdown of ADAMTS13 attenuates tube formation in trophoblast cells and extravillous trophoblast outgrowth in placental explants.","method":"RT-PCR, immunohistochemistry, Western blot, FRETS-VWF73 activity assay, MTT assay, wound scratch assay, transwell migration assay, tube formation assay, tissue outgrowth assay, ADAMTS13 knockdown","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cellular functional assays with recombinant protein and knockdown, single lab","pmids":["28751574"],"is_preprint":false},{"year":2017,"finding":"ADAMTS13 deficiency in diabetic mice promotes ventricular arrhythmias through aberrant connexin 43 distribution and increased CaMKII phosphorylation in cardiomyocytes. Thrombospondin-1 (TSP1) promotes CaMKII phosphorylation in cardiomyocytes in a paracrine manner, and ADAMTS13 acts to inhibit TSP1-induced CaMKII activation in vitro.","method":"Streptozotocin-induced diabetes in Adamts13-/- mice, dobutamine stress testing, connexin 43 immunolocalization, CaMKII phosphorylation assays, in vitro HL-1 cardiomyocyte TSP1/ADAMTS13 treatment","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo knockout phenotype plus in vitro mechanism, single lab, novel non-VWF function","pmids":["29976618"],"is_preprint":false},{"year":2018,"finding":"Recombinant ADAMTS13 treatment reduces NET burden in skin allografts and prolongs allograft survival in mice. Western blot and immunofluorescence microscopy showed NETs in allografts of vehicle-treated but not rhADAMTS13-treated mice 3 days post-surgery, identifying a novel mechanism of ADAMTS13 action in reducing neutrophil extracellular trap formation.","method":"Murine skin allograft model, immunofluorescence microscopy, Western blot for NETs, recombinant ADAMTS13 treatment","journal":"American journal of transplantation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct detection of mechanism (NET reduction) with functional outcome (allograft survival), single lab","pmids":["31730284"],"is_preprint":false},{"year":2017,"finding":"N-linked glycans of ADAMTS13 regulate its activity. Terminal sialic acid removal from metalloprotease domain glycans decreases ADAMTS13 activity. CUB domain glycan mutations (N1235Q and N1354Q) enhanced activity against both FRETS-VWF73 and VWF under shear, and reduced the CUB-spacer domain interaction (assessed by immunoprecipitation), confirming that CUB domain glycans modulate the closed/open conformational equilibrium. TSP2 domain glycan mutation (N707Q) reduced static but not flow activity.","method":"Enzymatic glycan removal, site-directed mutagenesis of N-linked glycan sites, kinetic assays under static and shear conditions, immunoprecipitation of CUB-spacer interaction","journal":"Journal of thrombosis and haemostasis : JTH","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic site mutagenesis with multiple functional readouts and structural interaction assay (immunoprecipitation), single lab but multiple methods","pmids":["28370891"],"is_preprint":false},{"year":2018,"finding":"In congenital TTP (Upshaw-Schulman syndrome), ADAMTS13 gene mutations alter ADAMTS13 conformation, with 87.5% of examined patients exhibiting abnormalities of ADAMTS13 conformation. Adult-onset USS is predominantly associated with the p.Arg1060Trp mutation (in 82% of adult-onset patients), suggesting this specific variant preferentially disrupts the spacer-CUB interaction that maintains ADAMTS13 in its folded conformation.","method":"ADAMTS13 conformation ELISA, genotyping of 56 USS patients, correlation of genotype with conformation","journal":"Thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conformation assay in patient cohort with genotype correlation, single lab","pmids":["30312976"],"is_preprint":false},{"year":2021,"finding":"Anti-cysteine/spacer (CS) domain autoantibodies from iTTP patients can disrupt the spacer-CUB interaction of folded ADAMTS13 (open its conformation). All purified anti-CS fractions from 10/10 patients tested were able to open ADAMTS13, while only 2/4 anti-CUB fractions opened ADAMTS13, establishing the anti-CS antibodies' mechanism of action as disrupting closed conformation.","method":"Affinity chromatography purification of anti-CS and anti-CUB autoantibody fractions, ADAMTS13 conformation ELISA","journal":"Blood advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — purified patient autoantibody fractions with conformation assay, single lab but well-controlled","pmids":["34559219"],"is_preprint":false},{"year":2017,"finding":"siRNA knockdown of endogenous ADAMTS13 in HUVEC reduced proliferation by 21%, abolished scratch wound migration, and decreased tube formation (tube length, size, junction numbers) by ~40%. ADAMTS13 knockdown decreased VEGF protein by 45% and downregulated AKT pathway activity, placing endogenous ADAMTS13 upstream of VEGF/AKT signaling in endothelial angiogenesis.","method":"siRNA knockdown of ADAMTS13 in HUVEC, proliferation assay, scratch wound assay, Matrigel tube formation assay, Western blot for VEGF and phospho-AKT","journal":"Microvascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific siRNA and multiple functional readouts, pathway placement by western blot, single lab","pmids":["28546076"],"is_preprint":false},{"year":2019,"finding":"ADAMTS13 deficiency in APP/PS1 Alzheimer's disease mice caused progressive blood-brain barrier breakdown, reduced vessel density, capillary perfusion, and cerebral blood flow, and accelerated Aβ accumulation. Viral-mediated ADAMTS13 expression in APPPS1 mice with established pathology attenuated BBB disruption, increased microvascular perfusion, increased BBB-mediated Aβ clearance, reduced plaque load, and improved cognitive performance.","method":"In vivo multiphoton microscopy, histological analysis, behavioral testing, viral vector ADAMTS13 overexpression in Adamts13-/-/APPPS1 mice","journal":"PLoS biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function with multiple orthogonal readouts, single lab","pmids":["31185010"],"is_preprint":false},{"year":2017,"finding":"ADAMTS13 deficiency exacerbates diabetic nephropathy through VWF-dependent intrarenal thrombosis. Adamts13-/- diabetic mice had worse kidney function and more intrarenal thrombosis than WT diabetic mice; genetic deletion of VWF in Adamts13-/- diabetic mice improved kidney function and inhibited intrarenal thrombosis, demonstrating that ADAMTS13 protects against diabetic nephropathy by inhibiting VWF-dependent thrombosis.","method":"Streptozotocin diabetic mouse model in Adamts13-/-, Vwf-/-, and Adamts13-/-Vwf-/- mice, renal function measurements, immunohistochemistry for thrombosis markers","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (triple genotype rescue experiment) with multiple functional readouts","pmids":["28495930"],"is_preprint":false}],"current_model":"ADAMTS13 is a constitutively active plasma zinc metalloprotease synthesized primarily by hepatic stellate cells (and also by endothelial cells, platelets, renal tubular cells, and trophoblasts) that cleaves the Tyr1605-Met1606 bond in the VWF A2 domain under fluid shear stress; its proteolytic activity is allosterically regulated by a closed-to-open conformational switch in which autoinhibitory CUB-spacer domain interactions suppress the metalloprotease active site, and binding of VWF's D4 domain (or activating antibodies) to the distal T8-CUB domains opens this conformation to allosterically activate the metalloprotease domain and enable proteolysis of platelet-VWF complexes; beyond VWF cleavage, ADAMTS13 promotes angiogenesis via TSP1 domain-mediated VEGF/VEGFR2 and AKT signaling, inhibits thrombospondin-1-induced CaMKII phosphorylation in cardiomyocytes, reduces NET formation, and attenuates VWF-dependent inflammation in multiple vascular disease models."},"narrative":{"mechanistic_narrative":"ADAMTS13 is a plasma zinc metalloprotease that regulates hemostasis by cleaving the Tyr1605-Met1606 bond in the von Willebrand factor (VWF) A2 domain, the physiologic VWF-cleaving activity confirmed by reconstitution with recombinant enzyme [PMID:11557746, PMID:12393399]. Cleavage is markedly enhanced when VWF is bound to platelets via GPIbalpha under fluid shear stress, preferentially consuming large, prothrombotic VWF multimers [PMID:17901248], and the enzyme is released constitutively from the Golgi of endothelial cells to cleave cell-anchored VWF strings [PMID:19822897]. Catalysis is allosterically controlled by a closed-to-open conformational switch: distal T8-CUB domains autoinhibit the metalloprotease active site through interactions with the proximal MDTCS region, and binding of the VWF D4 domain (or activating antibodies) to T7/T8-CUB relieves this autoinhibition by increasing kcat and opening the occluded active-site cleft [PMID:25512528, PMID:31439947, PMID:30700419, PMID:32196558]. Substrate engagement is staged through cysteine-rich and spacer exosites that dock VWF, followed by a disintegrin-like domain exosite that allosterically activates the protease, with metalloprotease subsites VR1/VR3 and CUB-domain N-glycans tuning specificity and the conformational equilibrium [PMID:20647566, PMID:31439947, PMID:28370891]. Beyond VWF proteolysis, ADAMTS13 acts through its TSP1 repeats to promote angiogenesis by inducing VEGF expression and VEGFR2/AKT signaling [PMID:22626948, PMID:24950743, PMID:28546076], and protects vascular beds in a VWF-dependent manner across atherosclerosis, diabetic nephropathy, and stroke models [PMID:24261607, PMID:28495930, PMID:28428179]. Mutations in ADAMTS13 that impair secretion, catalysis, or the spacer-CUB conformational interaction cause congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome), and patient autoantibodies against the cysteine/spacer region open the closed conformation in acquired TTP [PMID:12181489, PMID:30312976, PMID:34559219].","teleology":[{"year":2001,"claim":"Establishing the primary sequence and modular domain architecture defined ADAMTS13 as a multidomain reprolysin-type zinc metalloprotease and predicted zymogen activation, framing all subsequent structure-function work.","evidence":"cDNA cloning, Northern blotting, and domain architecture analysis","pmids":["11557746"],"confidence":"High","gaps":["Catalytic substrate not yet demonstrated","Mode of zymogen activation only inferred from furin site"]},{"year":2002,"claim":"Reconstitution with recombinant protein answered whether ADAMTS13 is itself the plasma VWF-cleaving protease, confirming identity and that TTP autoantibodies inhibit this activity.","evidence":"Recombinant ADAMTS13 in HEK293 cells, VWF multimer degradation assay, inhibition by TTP plasma","pmids":["12393399"],"confidence":"High","gaps":["Scissile bond and physiologic activation conditions not yet defined","Cellular source in vivo unaddressed"]},{"year":2002,"claim":"Mutagenesis of congenital TTP alleles distinguished two disease mechanisms—impaired secretion versus reduced catalytic activity—linking specific variants to loss of function.","evidence":"Expression of mutant ADAMTS13 in HeLa cells with secretion and activity readouts","pmids":["12181489"],"confidence":"High","gaps":["Conformational basis of dysfunction not yet known","Did not address acquired/autoantibody-mediated disease"]},{"year":2005,"claim":"Identifying hepatic stellate cells (and endothelial cells/platelets) as cellular sources answered where active ADAMTS13 originates, beyond the liver as an organ.","evidence":"In situ hybridization, cell fractionation with activity assays, RT-PCR, platelet lysate activity assays","pmids":["15806136","16176307"],"confidence":"Medium","gaps":["Relative contribution of each source to plasma pool unquantified","Regulation of cell-type-specific expression unknown"]},{"year":2007,"claim":"Demonstrating shear- and platelet-GPIbalpha-dependent enhancement of cleavage explained how ADAMTS13 selectively trims the largest, most thrombogenic VWF multimers under physiologic flow.","evidence":"Cone-plate viscometer shear assay with anti-GPIbalpha blocking and multimeric gel analysis","pmids":["17901248"],"confidence":"High","gaps":["Molecular mechanism of shear-induced substrate exposure not resolved here","Enzyme conformational change not yet linked"]},{"year":2007,"claim":"Mapping the VWF A2 N1574 glycan as a modulator of susceptibility connected substrate glycosylation (and ABO blood group) to cleavage efficiency.","evidence":"PNGase F digestion, lectin analysis, recombinant VWF-A2 mutagenesis, binding and proteolysis assays","pmids":["17975018"],"confidence":"High","gaps":["Mechanism by which glycan shields the scissile site not structurally defined"]},{"year":2008,"claim":"Kinetic and thermodynamic dissection identified VWF A2 'hot spot' residues and ionizable catalytic groups, and proposed a C-shaped enzyme conformation needed to orient the scissile bond.","evidence":"FRETS kinetic assays across pH/temperature, Co2+ substitution, product inhibition, molecular modeling","pmids":["18502798"],"confidence":"Medium","gaps":["Computational C-shape model not structurally validated at the time","Single-lab kinetic interpretation"]},{"year":2009,"claim":"Live-cell imaging established that endothelial ADAMTS13 is secreted constitutively via the Golgi and cleaves cell-anchored VWF strings, defining a local surveillance mechanism distinct from VWF storage.","evidence":"Live-cell HUVEC imaging, domain-specific blocking antibodies, VWF string cleavage assay","pmids":["19822897"],"confidence":"High","gaps":["Quantitative contribution of endothelial vs plasma enzyme to string cleavage unclear"]},{"year":2010,"claim":"Subsite mutagenesis localized determinants of catalytic efficiency (VR1) and P1' specificity (VR3) within the metalloprotease domain, refining the active-site model.","evidence":"Domain swapping with ADAMTS1/2, site-directed mutagenesis, kinetics with VWF115","pmids":["20647566"],"confidence":"High","gaps":["Did not address distal-domain allosteric control of these subsites"]},{"year":2014,"claim":"SAXS plus truncation kinetics revealed distal T8-CUB autoinhibition relieved by VWF D4 binding, establishing substrate-induced allosteric activation as the core regulatory logic.","evidence":"Kinetic assays with truncated variants, SAXS, monoclonal antibody domain blocking","pmids":["25512528"],"confidence":"High","gaps":["Atomic structure of closed conformation not yet available","Precise distal contact residues unresolved"]},{"year":2019,"claim":"A crystal structure of the metalloprotease-to-spacer region captured the latent occluded active site and ordered the exosite engagement steps, showing VWF serves as both cofactor and substrate; complementary phylogenetic deletion work pinpointed T7/T8 as the essential allosteric switches.","evidence":"X-ray crystallography with exosite mutagenesis; domain deletion across 20 species with shear-dependent cleavage assays","pmids":["31439947","30700419"],"confidence":"High","gaps":["Full-length closed conformation structure still lacking","T3-T6 function (dispensable here) unexplained"]},{"year":2020,"claim":"Kinetic dissection of antibody-induced activation showed the open conformation increases kcat without changing Km, localizing the allosteric effect to the metalloprotease active site rather than exosite exposure.","evidence":"Km/kcat kinetics, conformation ELISA, anti-spacer and anti-CUB1 monoclonal antibodies","pmids":["32196558"],"confidence":"High","gaps":["Physiologic trigger of the cryptic-epitope exposure in vivo not defined"]},{"year":2017,"claim":"Systematic N-glycan mutagenesis showed CUB-domain glycans modulate the CUB-spacer interaction and thus the closed/open equilibrium, linking glycosylation directly to conformational regulation.","evidence":"Enzymatic glycan removal, site-directed glycan-site mutagenesis, static/shear kinetics, immunoprecipitation of CUB-spacer interaction","pmids":["28370891"],"confidence":"High","gaps":["In vivo regulation of glycan occupancy not addressed"]},{"year":2018,"claim":"Conformation profiling of congenital and acquired TTP established that disease-causing mutations and anti-CS autoantibodies act by disrupting the spacer-CUB interaction that keeps ADAMTS13 folded.","evidence":"Conformation ELISA with USS genotyping; affinity-purified anti-CS/anti-CUB autoantibody fractions","pmids":["30312976","34559219"],"confidence":"Medium","gaps":["Single-lab conformation assay","Causal link from open conformation to clinical phenotype not directly demonstrated"]},{"year":2012,"claim":"Cellular and Co-IP studies revealed a VWF-independent role: ADAMTS13 TSP1 repeats bind VEGF and promote endothelial proliferation, migration, and tube formation.","evidence":"Matrigel/Boyden/proliferation assays, co-immunoprecipitation, domain truncation; receptor-mediated endocytosis by mannose receptor on dendritic cells","pmids":["22626948","22289891"],"confidence":"Medium","gaps":["Pro- vs anti-angiogenic effects context-dependent and unreconciled","In vivo relevance of TSP1-VEGF binding not shown here"]},{"year":2017,"claim":"Loss- and gain-of-function studies placed endogenous ADAMTS13 upstream of VEGF/VEGFR2/AKT signaling and defined its protective vascular roles via VWF-dependent epistasis in stroke, diabetic nephropathy, and atherosclerosis.","evidence":"siRNA knockdown in HUVEC with VEGF/AKT/VEGFR2 readouts; Adamts13-/-/Vwf-/- double/triple knockout mouse epistasis in stroke, nephropathy, and atherosclerosis models","pmids":["28546076","24950743","28428179","28495930","24261607"],"confidence":"High","gaps":["Whether vascular protection requires proteolytic activity or TSP1-mediated signaling not always separated","Cell-of-origin of the relevant ADAMTS13 in vivo unclear"]},{"year":2019,"claim":"Studies in placenta, cardiomyocytes, Alzheimer's models, and allografts extended ADAMTS13 function to trophoblast invasion, inhibition of TSP1-induced CaMKII signaling, blood-brain barrier maintenance/Abeta clearance, and reduction of NET formation.","evidence":"Knockdown/recombinant protein in trophoblasts; Adamts13-/- diabetic heart and APPPS1 brain models with viral rescue; murine skin allograft NET imaging","pmids":["28751574","29976618","31185010","31730284"],"confidence":"Medium","gaps":["Molecular substrates/partners in these tissues largely undefined","Single-lab models for each novel function","Dependence on metalloprotease activity vs TSP1 signaling not resolved"]},{"year":null,"claim":"How the physiologic open-conformation trigger, glycosylation state, and tissue-specific non-VWF functions are integrated and regulated in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No full-length closed-conformation structure","Substrates for non-VWF/TSP1-mediated functions unidentified","Endogenous activators of the conformational switch in vivo undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4,5,6,9]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,12]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,9,11]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,5,13]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[1,4,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,27,28]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[20,24,29]}],"complexes":[],"partners":["VWF","GP1BA","VEGFA","THBS1","MRC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q76LX8","full_name":"A disintegrin and metalloproteinase with thrombospondin motifs 13","aliases":["von Willebrand factor-cleaving protease","vWF-CP","vWF-cleaving protease"],"length_aa":1427,"mass_kda":153.6,"function":"Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q76LX8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADAMTS13","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADAMTS13","total_profiled":1310},"omim":[{"mim_id":"613554","title":"VON WILLEBRAND DISEASE, TYPE 2; VWD2","url":"https://www.omim.org/entry/613554"},{"mim_id":"613160","title":"VON WILLEBRAND FACTOR; VWF","url":"https://www.omim.org/entry/613160"},{"mim_id":"604134","title":"A DISINTEGRIN-LIKE AND METALLOPROTEASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 13; ADAMTS13","url":"https://www.omim.org/entry/604134"},{"mim_id":"602647","title":"NUCLEAR RNA EXPORT FACTOR 1; NXF1","url":"https://www.omim.org/entry/602647"},{"mim_id":"274150","title":"THROMBOTIC THROMBOCYTOPENIC PURPURA, HEREDITARY; TTP","url":"https://www.omim.org/entry/274150"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Vesicles","reliability":"Uncertain"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":62.5}],"url":"https://www.proteinatlas.org/search/ADAMTS13"},"hgnc":{"alias_symbol":["VWFCP","TTP","vWF-CP","FLJ42993","MGC118899","MGC118900","DKFZp434C2322"],"prev_symbol":["C9orf8"]},"alphafold":{"accession":"Q76LX8","domains":[{"cath_id":"3.40.390.10","chopping":"78-286","consensus_level":"medium","plddt":89.0227,"start":78,"end":286},{"cath_id":"3.40.1620.60","chopping":"299-384","consensus_level":"medium","plddt":83.253,"start":299,"end":384},{"cath_id":"-","chopping":"404-412_430-458_467-541","consensus_level":"high","plddt":92.9727,"start":404,"end":541},{"cath_id":"2.60.120.830","chopping":"549-681","consensus_level":"high","plddt":94.477,"start":549,"end":681},{"cath_id":"2.60.120.290","chopping":"1192-1296","consensus_level":"medium","plddt":83.0526,"start":1192,"end":1296},{"cath_id":"2.60.120.290","chopping":"1302-1410","consensus_level":"high","plddt":77.536,"start":1302,"end":1410}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q76LX8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q76LX8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q76LX8-F1-predicted_aligned_error_v6.png","plddt_mean":75.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADAMTS13","jax_strain_url":"https://www.jax.org/strain/search?query=ADAMTS13"},"sequence":{"accession":"Q76LX8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q76LX8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q76LX8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q76LX8"}},"corpus_meta":[{"pmid":"11557746","id":"PMC_11557746","title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11557746","citation_count":672,"is_preprint":false},{"pmid":"12181489","id":"PMC_12181489","title":"Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12181489","citation_count":324,"is_preprint":false},{"pmid":"21715306","id":"PMC_21715306","title":"Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21715306","citation_count":236,"is_preprint":false},{"pmid":"25587650","id":"PMC_25587650","title":"ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.","date":"2015","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25587650","citation_count":192,"is_preprint":false},{"pmid":"12393399","id":"PMC_12393399","title":"Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393399","citation_count":190,"is_preprint":false},{"pmid":"33230904","id":"PMC_33230904","title":"The ADAMTS13-von Willebrand factor axis in COVID-19 patients.","date":"2020","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/33230904","citation_count":175,"is_preprint":false},{"pmid":"21781265","id":"PMC_21781265","title":"Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan.","date":"2011","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/21781265","citation_count":153,"is_preprint":false},{"pmid":"15806136","id":"PMC_15806136","title":"ADAMTS13 is expressed in hepatic stellate cells.","date":"2005","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15806136","citation_count":142,"is_preprint":false},{"pmid":"19847791","id":"PMC_19847791","title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19847791","citation_count":138,"is_preprint":false},{"pmid":"17901248","id":"PMC_17901248","title":"Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17901248","citation_count":132,"is_preprint":false},{"pmid":"17053057","id":"PMC_17053057","title":"ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17053057","citation_count":109,"is_preprint":false},{"pmid":"23809107","id":"PMC_23809107","title":"Structure-function and regulation of ADAMTS-13 protease.","date":"2013","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/23809107","citation_count":105,"is_preprint":false},{"pmid":"19822897","id":"PMC_19822897","title":"Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19822897","citation_count":104,"is_preprint":false},{"pmid":"25512528","id":"PMC_25512528","title":"Allosteric activation of ADAMTS13 by von Willebrand factor.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25512528","citation_count":103,"is_preprint":false},{"pmid":"28428179","id":"PMC_28428179","title":"ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28428179","citation_count":94,"is_preprint":false},{"pmid":"33343584","id":"PMC_33343584","title":"Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33343584","citation_count":90,"is_preprint":false},{"pmid":"16176307","id":"PMC_16176307","title":"Platelet-derived VWF-cleaving metalloprotease ADAMTS-13.","date":"2005","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/16176307","citation_count":86,"is_preprint":false},{"pmid":"33893632","id":"PMC_33893632","title":"Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.","date":"2021","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/33893632","citation_count":81,"is_preprint":false},{"pmid":"17975018","id":"PMC_17975018","title":"N-linked glycosylation of VWF modulates its interaction with ADAMTS13.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17975018","citation_count":81,"is_preprint":false},{"pmid":"31439947","id":"PMC_31439947","title":"Crystal structure and substrate-induced activation of ADAMTS13.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31439947","citation_count":71,"is_preprint":false},{"pmid":"14727254","id":"PMC_14727254","title":"von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.","date":"2004","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14727254","citation_count":71,"is_preprint":false},{"pmid":"12172456","id":"PMC_12172456","title":"ADAMTS13 and TTP.","date":"2002","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/12172456","citation_count":65,"is_preprint":false},{"pmid":"34053187","id":"PMC_34053187","title":"ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.","date":"2021","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/34053187","citation_count":60,"is_preprint":false},{"pmid":"20196724","id":"PMC_20196724","title":"The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure?","date":"2010","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20196724","citation_count":59,"is_preprint":false},{"pmid":"23233642","id":"PMC_23233642","title":"Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.","date":"2012","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/23233642","citation_count":57,"is_preprint":false},{"pmid":"27737864","id":"PMC_27737864","title":"Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.","date":"2016","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27737864","citation_count":57,"is_preprint":false},{"pmid":"30312976","id":"PMC_30312976","title":"ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome.","date":"2018","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/30312976","citation_count":53,"is_preprint":false},{"pmid":"23433535","id":"PMC_23433535","title":"Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia.","date":"2013","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/23433535","citation_count":48,"is_preprint":false},{"pmid":"22626948","id":"PMC_22626948","title":"ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis.","date":"2012","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/22626948","citation_count":43,"is_preprint":false},{"pmid":"22289891","id":"PMC_22289891","title":"The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22289891","citation_count":42,"is_preprint":false},{"pmid":"36074019","id":"PMC_36074019","title":"Mechanisms of ADAMTS13 regulation.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/36074019","citation_count":40,"is_preprint":false},{"pmid":"29793936","id":"PMC_29793936","title":"Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29793936","citation_count":39,"is_preprint":false},{"pmid":"20705333","id":"PMC_20705333","title":"Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro.","date":"2010","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/20705333","citation_count":39,"is_preprint":false},{"pmid":"31409673","id":"PMC_31409673","title":"Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31409673","citation_count":39,"is_preprint":false},{"pmid":"22212812","id":"PMC_22212812","title":"ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.","date":"2012","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/22212812","citation_count":39,"is_preprint":false},{"pmid":"30655285","id":"PMC_30655285","title":"The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.","date":"2019","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/30655285","citation_count":38,"is_preprint":false},{"pmid":"32196558","id":"PMC_32196558","title":"Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32196558","citation_count":38,"is_preprint":false},{"pmid":"18574602","id":"PMC_18574602","title":"Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.","date":"2008","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/18574602","citation_count":38,"is_preprint":false},{"pmid":"12395148","id":"PMC_12395148","title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.","date":"2002","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/12395148","citation_count":38,"is_preprint":false},{"pmid":"33991361","id":"PMC_33991361","title":"Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond.","date":"2021","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33991361","citation_count":36,"is_preprint":false},{"pmid":"20647566","id":"PMC_20647566","title":"The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20647566","citation_count":36,"is_preprint":false},{"pmid":"25213289","id":"PMC_25213289","title":"Acquired TTP: ADAMTS13 meets the immune system.","date":"2014","source":"Blood reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25213289","citation_count":34,"is_preprint":false},{"pmid":"24261607","id":"PMC_24261607","title":"ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism.","date":"2014","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/24261607","citation_count":34,"is_preprint":false},{"pmid":"30461292","id":"PMC_30461292","title":"ADAMTS13 protects mice against renal ischemia-reperfusion injury by reducing inflammation and improving endothelial function.","date":"2018","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30461292","citation_count":34,"is_preprint":false},{"pmid":"16388417","id":"PMC_16388417","title":"Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.","date":"2005","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/16388417","citation_count":33,"is_preprint":false},{"pmid":"14727258","id":"PMC_14727258","title":"Assays of ADAMTS-13 activity.","date":"2004","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14727258","citation_count":32,"is_preprint":false},{"pmid":"31758651","id":"PMC_31758651","title":"Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis.","date":"2019","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/31758651","citation_count":32,"is_preprint":false},{"pmid":"21535387","id":"PMC_21535387","title":"Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura.","date":"2011","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/21535387","citation_count":32,"is_preprint":false},{"pmid":"19141866","id":"PMC_19141866","title":"Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19141866","citation_count":32,"is_preprint":false},{"pmid":"24950743","id":"PMC_24950743","title":"ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2.","date":"2014","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/24950743","citation_count":30,"is_preprint":false},{"pmid":"28751574","id":"PMC_28751574","title":"Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28751574","citation_count":30,"is_preprint":false},{"pmid":"16388413","id":"PMC_16388413","title":"Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.","date":"2005","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/16388413","citation_count":29,"is_preprint":false},{"pmid":"29367415","id":"PMC_29367415","title":"Recombinant Human ADAMTS13 Treatment Improves Myocardial Remodeling and Functionality After Pressure Overload Injury in Mice.","date":"2018","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/29367415","citation_count":29,"is_preprint":false},{"pmid":"30208220","id":"PMC_30208220","title":"ADAMTS13: origins, applications, and prospects.","date":"2018","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/30208220","citation_count":28,"is_preprint":false},{"pmid":"31185010","id":"PMC_31185010","title":"ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology.","date":"2019","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/31185010","citation_count":28,"is_preprint":false},{"pmid":"31638892","id":"PMC_31638892","title":"VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.","date":"2019","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/31638892","citation_count":28,"is_preprint":false},{"pmid":"30235483","id":"PMC_30235483","title":"Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.","date":"2018","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/30235483","citation_count":28,"is_preprint":false},{"pmid":"26581428","id":"PMC_26581428","title":"ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.","date":"2015","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/26581428","citation_count":27,"is_preprint":false},{"pmid":"30700419","id":"PMC_30700419","title":"Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30700419","citation_count":27,"is_preprint":false},{"pmid":"14727256","id":"PMC_14727256","title":"Expression and characterization of recombinant human ADAMTS-13.","date":"2004","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14727256","citation_count":26,"is_preprint":false},{"pmid":"25242241","id":"PMC_25242241","title":"Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review.","date":"2014","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/25242241","citation_count":26,"is_preprint":false},{"pmid":"34505883","id":"PMC_34505883","title":"Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34505883","citation_count":26,"is_preprint":false},{"pmid":"28102428","id":"PMC_28102428","title":"Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.","date":"2017","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/28102428","citation_count":25,"is_preprint":false},{"pmid":"19644711","id":"PMC_19644711","title":"Biologically active ADAMTS13 is expressed in renal tubular epithelial cells.","date":"2010","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/19644711","citation_count":25,"is_preprint":false},{"pmid":"27771173","id":"PMC_27771173","title":"Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies.","date":"2016","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27771173","citation_count":24,"is_preprint":false},{"pmid":"28495930","id":"PMC_28495930","title":"ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28495930","citation_count":24,"is_preprint":false},{"pmid":"15662617","id":"PMC_15662617","title":"Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies.","date":"2005","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/15662617","citation_count":23,"is_preprint":false},{"pmid":"27696191","id":"PMC_27696191","title":"ADAMTS13: more than a regulator of thrombosis.","date":"2016","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/27696191","citation_count":22,"is_preprint":false},{"pmid":"35327035","id":"PMC_35327035","title":"The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.","date":"2022","source":"Healthcare (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35327035","citation_count":22,"is_preprint":false},{"pmid":"18502798","id":"PMC_18502798","title":"Mechanistic studies on ADAMTS13 catalysis.","date":"2008","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18502798","citation_count":22,"is_preprint":false},{"pmid":"17173498","id":"PMC_17173498","title":"ADAMTS13 and microvascular thrombosis.","date":"2006","source":"Expert review of cardiovascular therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17173498","citation_count":21,"is_preprint":false},{"pmid":"33606732","id":"PMC_33606732","title":"Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33606732","citation_count":21,"is_preprint":false},{"pmid":"21720563","id":"PMC_21720563","title":"Phenotypic expression of ADAMTS13 in glomerular endothelial cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21720563","citation_count":21,"is_preprint":false},{"pmid":"16113782","id":"PMC_16113782","title":"Transcriptional regulation of ADAMTS13.","date":"2005","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/16113782","citation_count":20,"is_preprint":false},{"pmid":"32075652","id":"PMC_32075652","title":"ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32075652","citation_count":19,"is_preprint":false},{"pmid":"29777164","id":"PMC_29777164","title":"mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29777164","citation_count":19,"is_preprint":false},{"pmid":"39125707","id":"PMC_39125707","title":"ADAMTS13 in the New Era of TTP.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39125707","citation_count":18,"is_preprint":false},{"pmid":"33212380","id":"PMC_33212380","title":"ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis.","date":"2020","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/33212380","citation_count":18,"is_preprint":false},{"pmid":"33226724","id":"PMC_33226724","title":"ADAMTS13 inhibits oxidative stress and ameliorates progressive chronic kidney disease following ischaemia/reperfusion injury.","date":"2020","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33226724","citation_count":18,"is_preprint":false},{"pmid":"35443560","id":"PMC_35443560","title":"Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.","date":"2022","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/35443560","citation_count":18,"is_preprint":false},{"pmid":"24106608","id":"PMC_24106608","title":"Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases.","date":"2013","source":"Mediterranean journal of hematology and infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24106608","citation_count":17,"is_preprint":false},{"pmid":"31730284","id":"PMC_31730284","title":"Recombinant human ADAMTS13 treatment and anti-NET strategies enhance skin allograft survival in mice.","date":"2019","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/31730284","citation_count":17,"is_preprint":false},{"pmid":"29304523","id":"PMC_29304523","title":"Insights into 3D Structure of ADAMTS13: A Stepping Stone towards Novel Therapeutic Treatment of Thrombotic Thrombocytopenic Purpura.","date":"2018","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/29304523","citation_count":16,"is_preprint":false},{"pmid":"34559219","id":"PMC_34559219","title":"Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34559219","citation_count":15,"is_preprint":false},{"pmid":"23715102","id":"PMC_23715102","title":"ADAMTS13 activity and genetic mutations in Japan.","date":"2013","source":"Hamostaseologie","url":"https://pubmed.ncbi.nlm.nih.gov/23715102","citation_count":14,"is_preprint":false},{"pmid":"26038528","id":"PMC_26038528","title":"ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.","date":"2015","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/26038528","citation_count":14,"is_preprint":false},{"pmid":"37834813","id":"PMC_37834813","title":"ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura.","date":"2023","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37834813","citation_count":13,"is_preprint":false},{"pmid":"15981755","id":"PMC_15981755","title":"VWF-cleaving protease (ADAMTS13) in premature infants.","date":"2005","source":"Acta paediatrica (Oslo, Norway : 1992)","url":"https://pubmed.ncbi.nlm.nih.gov/15981755","citation_count":13,"is_preprint":false},{"pmid":"18006046","id":"PMC_18006046","title":"Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxinemia.","date":"2007","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/18006046","citation_count":13,"is_preprint":false},{"pmid":"32685903","id":"PMC_32685903","title":"Generation and validation of small ADAMTS13 fragments for epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura.","date":"2020","source":"Research and practice in thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/32685903","citation_count":13,"is_preprint":false},{"pmid":"32726827","id":"PMC_32726827","title":"Current and Future Perspectives on ADAMTS13 and Thrombotic Thrombocytopenic Purpura.","date":"2020","source":"Hamostaseologie","url":"https://pubmed.ncbi.nlm.nih.gov/32726827","citation_count":12,"is_preprint":false},{"pmid":"28370891","id":"PMC_28370891","title":"ADAMTS-13 glycans and conformation-dependent activity.","date":"2017","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/28370891","citation_count":12,"is_preprint":false},{"pmid":"21238935","id":"PMC_21238935","title":"Structure and proteolytic properties of ADAMTS13, a metalloprotease involved in the pathogenesis of thrombotic microangiopathies.","date":"2011","source":"Progress in molecular biology and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/21238935","citation_count":12,"is_preprint":false},{"pmid":"30745808","id":"PMC_30745808","title":"Von Willebrand Factor Adhesive Activity and ADAMTS13 Protease Activity in HIV-1-Infected Men.","date":"2019","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30745808","citation_count":12,"is_preprint":false},{"pmid":"36368692","id":"PMC_36368692","title":"From the Discovery of ADAMTS13 to Current Understanding of Its Role in Health and Disease.","date":"2022","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/36368692","citation_count":11,"is_preprint":false},{"pmid":"25010251","id":"PMC_25010251","title":"Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.","date":"2014","source":"Hamostaseologie","url":"https://pubmed.ncbi.nlm.nih.gov/25010251","citation_count":11,"is_preprint":false},{"pmid":"34564132","id":"PMC_34564132","title":"The Intriguing Relationships of von Willebrand Factor, ADAMTS13 and Cardiac Disease.","date":"2021","source":"Journal of cardiovascular development and disease","url":"https://pubmed.ncbi.nlm.nih.gov/34564132","citation_count":11,"is_preprint":false},{"pmid":"29976618","id":"PMC_29976618","title":"ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes.","date":"2018","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/29976618","citation_count":11,"is_preprint":false},{"pmid":"28546076","id":"PMC_28546076","title":"siRNA-knockdown of ADAMTS-13 modulates endothelial cell angiogenesis.","date":"2017","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/28546076","citation_count":11,"is_preprint":false},{"pmid":"39851513","id":"PMC_39851513","title":"ADAMTS13 Improves Endothelial Function and Reduces Inflammation in Diabetic Retinopathy.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/39851513","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53628,"output_tokens":8764,"usd":0.146172,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18786,"output_tokens":5193,"usd":0.111878,"stage2_stop_reason":"end_turn"},"total_usd":0.25805,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"ADAMTS13 (VWFCP) is a 1427-amino-acid metalloprotease with a domain architecture comprising: signal peptide, short propeptide (ending in RQRR furin cleavage site), reprolysin-like metalloprotease domain, disintegrin-like domain, thrombospondin-1 repeat, Cys-rich domain, spacer domain, seven additional TSP1 repeats, and two CUB domains. The protein contains conserved Zn2+ and Ca2+ binding sites in the protease domain. Northern blotting detected full-length mRNA only in liver. The protein is apparently synthesized as a zymogen requiring proteolytic activation, possibly by furin.\",\n      \"method\": \"cDNA cloning, Northern blotting, domain architecture analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — foundational molecular cloning with functional domain characterization, replicated across multiple subsequent studies\",\n      \"pmids\": [\"11557746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Recombinant ADAMTS13 expressed in HEK293 cells degrades VWF multimers and proteolytically cleaves VWF to the same fragments generated by plasma VWF-cleaving protease, confirming ADAMTS13 is the physiologic VWF-cleaving metalloprotease. Recombinant ADAMTS13-mediated VWF degradation was entirely inhibited by plasma from an acquired TTP patient (containing inhibitory autoantibodies).\",\n      \"method\": \"Expression of recombinant ADAMTS13 in HEK293 cells, VWF multimer degradation assay, inhibition by TTP patient plasma\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional reconstitution with recombinant protein, replicated by independent groups\",\n      \"pmids\": [\"12393399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Missense mutations R268P and C508Y in ADAMTS13 abolish enzyme activity by preventing secretion from cells. Nonsense mutation Q449stop and missense P475S produce secreted protein with minimal or reduced activity respectively, demonstrating that defects in both protein secretion and catalytic activity are mechanisms underlying congenital TTP.\",\n      \"method\": \"Expression analysis of mutant ADAMTS13 in HeLa cells, activity assays, secretion analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure-function mutagenesis with orthogonal secretion and activity readouts, confirmed in cell culture\",\n      \"pmids\": [\"12181489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ADAMTS13 is expressed primarily by hepatic stellate cells in the liver. In situ hybridization, cell fractionation with proteolytic activity measurement in conditioned media, and RT-PCR of isolated hepatic stellate cells all identified this cell type as the primary hepatic source. Mouse ADAMTS13 cloned from hepatic stellate cells was active against VWF and inhibited by EDTA or TTP patient IgG inhibitors.\",\n      \"method\": \"In situ hybridization, cell fractionation with activity assays, RT-PCR, cloning from primary hepatic stellate cells\",\n      \"journal\": \"Laboratory investigation; a journal of technical methods and pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ISH, fractionation with functional assay, RT-PCR) converging on same conclusion\",\n      \"pmids\": [\"15806136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ADAMTS13 preferentially cleaves platelet-VWF complexes under fluid shear stress. Platelet-dependent cleavage was blocked by anti-GPIbalpha monoclonal antibody or soluble GPIbalpha fragment, demonstrating that platelet binding to VWF via GPIbalpha is required for this enhanced proteolysis. Shear and platelet-dependent cleavage preferentially consumed large VWF multimers.\",\n      \"method\": \"Cone-plate viscometer shear assay, blocking antibodies against GPIbalpha, multimeric gel analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional blocking experiments with antibody and recombinant fragment, multiple orthogonal methods\",\n      \"pmids\": [\"17901248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADAMTS13 is released constitutively from endothelial cells directly from the Golgi to the cell exterior, without storage in an organelle (unlike VWF which is stored in Weibel-Palade bodies). HUVEC-released ADAMTS13 cleaves secreted and cell-anchored VWF strings at the Y1605-M1606 bond within 15 minutes. Blocking antibodies against different ADAMTS13 domains detected ADAMTS13 attachment along the lengths of VWF strings on the endothelial surface.\",\n      \"method\": \"Live-cell imaging of HUVEC, immunofluorescence with domain-specific antibodies, VWF cleavage assay under static conditions\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiment with functional consequence (VWF string cleavage), multiple domain-specific blocking antibodies\",\n      \"pmids\": [\"19822897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Two subsites in the ADAMTS13 metalloprotease domain are critical for function: VR1 (D187-R193) contains residues D187, R190, and R193 that influence cleavage efficiency (point mutants reduce kcat/Km 2-10 fold); VR3 residues D252-P256 influence P1' amino acid specificity, shaping the S1' substrate-binding pocket.\",\n      \"method\": \"Domain swapping between ADAMTS13 and ADAMTS1/2, site-directed mutagenesis, kinetic analysis with VWF115 substrate\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis with kinetic analysis identifying catalytic subsites\",\n      \"pmids\": [\"20647566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"N-linked glycan at position N1574 in the VWF A2 domain modulates ADAMTS13 interaction; mutation of N1574 increased VWF susceptibility to ADAMTS13 proteolysis and allowed cleavage in the absence of urea. N1515 mutation did not alter ADAMTS13 binding or proteolysis rate. ABO blood group sugars are presented on N-linked glycans at N1515 and N1574.\",\n      \"method\": \"PNGase F digestion, lectin analysis, recombinant VWF mutagenesis, binding and proteolysis assays with isolated VWF-A2 domain\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with recombinant mutant VWF, multiple orthogonal assays\",\n      \"pmids\": [\"17975018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The distal T8-CUB2 domains of ADAMTS13 markedly inhibit substrate cleavage (autoinhibition). Binding of VWF (specifically the D4 domain) or monoclonal antibodies to distal ADAMTS13 domains relieves this autoinhibition. Small angle X-ray scattering demonstrated that distal T-CUB domains physically interact with proximal MDTCS domains in the resting state, supporting substrate-induced allosteric activation.\",\n      \"method\": \"Kinetic assays with truncated ADAMTS13 variants, SAXS, monoclonal antibody-mediated domain blocking\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — SAXS structural data combined with kinetic functional assays and mutagenesis/truncation analysis\",\n      \"pmids\": [\"25512528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of ADAMTS13 metalloprotease-to-spacer domains reveals the metalloprotease domain in a latent conformation with an occluded active-site cleft. Kinetic analyses showed that binding of the ADAMTS13 cysteine-rich and spacer domain exosites to VWF brings enzyme and substrate into proximity, then binding of the disintegrin-like domain exosite to VWF allosterically activates the adjacent metalloprotease domain by opening the active-site cleft. VWF thus functions as both the activating cofactor and substrate for ADAMTS13.\",\n      \"method\": \"X-ray crystallography, kinetic analysis, exosite mutagenesis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus kinetic functional validation in a single rigorous study\",\n      \"pmids\": [\"31439947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"T7 and T8 distal domains of ADAMTS13 are essential for allosteric activation by VWF; deletion of either T7 or T8 abolished allosteric activation. In contrast, T3-T6 domains are dispensable: pigeon ADAMTS13 with only 3 distal T domains retained normal allosteric regulation and shear-dependent VWF cleavage. Human ADAMTS13 engineered to resemble pigeon ADAMTS13 (lacking T3-T6) retained normal allosteric regulation.\",\n      \"method\": \"Phylogenetic analysis, domain deletion variants, kinetic assays across 20 mammalian/avian/amphibian species, shear-dependent cleavage assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic domain deletion with functional reconstitution across multiple species and constructs\",\n      \"pmids\": [\"30700419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Antibody-induced conformational activation of ADAMTS13 (from closed/folded to open conformation) enhances ADAMTS13 proteolytic function by increasing kcat (turnover), not by augmenting substrate binding (Km unchanged). This mechanism is allosteric, acting on the metalloprotease domain active site, not via exposure of cysteine-rich or spacer domain exosites. Conformational extension exposes a cryptic epitope in the metalloprotease domain that is normally concealed in the closed conformation.\",\n      \"method\": \"Kinetic analysis (Km, kcat, kcat/Km), conformation ELISA, domain-specific monoclonal antibodies (anti-Spacer 3E4, anti-CUB1 17G2)\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous kinetic dissection with two orthogonal activating antibodies, mechanistic resolution of kcat vs Km\",\n      \"pmids\": [\"32196558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ADAMTS13 catalysis of Tyr1605-Met1606 bond hydrolysis in VWF is governed by two ionizable groups (pKa 6.41 and ~4.0). The transition state has negative activation entropy, indicating an ordered transition state. The VWF Met1606-Arg1668 product acts as a hyperbolic mixed-type inhibitor. Residues Asp1653, Glu1655, Glu1660, Asp1663, and Thr1656 in VWF A2 form a 'hot spot' driving molecular recognition by ADAMTS13. A molecular model indicates ADAMTS13 must adopt a C-like shape to accommodate substrate and properly orient the scissile bond.\",\n      \"method\": \"Fluorescence quenching (FRETS) kinetic assays across temperature and pH ranges, Co2+ substitution, product inhibition analysis, molecular modeling\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous in vitro kinetic analysis but single lab, computational model not independently validated\",\n      \"pmids\": [\"18502798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ADAMTS13 is also synthesized and secreted by vascular endothelial cells, and platelet lysates contain functionally active ADAMTS13 that cleaves endothelial cell-derived ultra-large VWF under static and flow conditions. Platelet surface ADAMTS13 expression increases upon activation by thrombin receptor-activating peptide but not ADP. The platelet-derived ADAMTS13 activity is inhibited by EDTA and by TTP patient anti-ADAMTS13 IgG.\",\n      \"method\": \"ADAMTS13 activity assay in platelet lysates, anti-ADAMTS13 antibody blocking, flow-based VWF cleavage assay, platelet activation assays\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional activity demonstrated with blocking antibodies and flow assays, single lab but multiple methods\",\n      \"pmids\": [\"16176307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Biologically active ADAMTS13 is expressed and secreted by human renal tubular epithelial cells (primary HRTEC and A498 cell line), demonstrated by RT-PCR, immunofluorescence, immunoblotting, and proteolytic cleavage of FRETS-VWF73 substrate. ADAMTS13 was also detected in situ in proximal and distal renal tubules in normal human kidney and was present in urine of patients with tubulopathy (but not normal urine), indicating the protease originates in tubuli.\",\n      \"method\": \"Real-time PCR, immunofluorescence, immunoblotting, FRETS-VWF73 substrate cleavage assay, immunohistochemistry, urine analysis\",\n      \"journal\": \"Pediatric nephrology (Berlin, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods demonstrating expression, localization, and functional activity, single lab\",\n      \"pmids\": [\"19644711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Human glomerular endothelial cells express, secrete, and produce functionally active ADAMTS13, demonstrated by real-time PCR, flow cytometry, immunofluorescence, immunoblotting, and VWF cleavage assays. ADAMTS13-deficient mice showed thickening of glomerular capillaries with platelet deposition on vessel walls, indicating ADAMTS13 protects against glomerular platelet deposition.\",\n      \"method\": \"RT-PCR, flow cytometry, immunofluorescence, immunoblotting, VWF cleavage assay, immunohistochemistry of Adamts13-/- vs wild-type mouse kidneys\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in cell culture plus knockout mouse phenotype, single lab\",\n      \"pmids\": [\"21720563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Thrombospondin-1 (TSP1) competitively inhibits ADAMTS13 binding and cleavage of VWF by binding to VWF A2 and A3 domains. TSP1 partially blocked ADAMTS13 binding to A2 and A3 domains and full-length VWF, and inhibited ADAMTS13 activity by up to 70% in vitro.\",\n      \"method\": \"ELISA-based binding assay with recombinant VWF A1/A2/A3 domains, western blot, residual collagen binding assay for ADAMTS13 activity\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — competitive binding and functional inhibition demonstrated by two orthogonal assays, single lab\",\n      \"pmids\": [\"20705333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ADAMTS13 is endocytosed by immature monocyte-derived dendritic cells via the macrophage mannose receptor (MR). Endocytosis was blocked by EGTA (Ca2+-dependent), mannan (competing mannose sugar), and an anti-MR blocking monoclonal antibody. siRNA silencing of MR reduced ADAMTS13 uptake. In vitro binding studies confirmed interaction between ADAMTS13 sugar moieties and the carbohydrate recognition domains of MR.\",\n      \"method\": \"Flow cytometry, confocal microscopy, siRNA knockdown of MR, in vitro binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal evidence from blocking antibody, siRNA knockdown, and direct binding assay; multiple orthogonal methods converging\",\n      \"pmids\": [\"22289891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Recombinant ADAMTS13 promotes endothelial cell tube formation, proliferation, and migration in a dose-dependent manner. ADAMTS13 inhibits VEGF-induced angiogenesis, and this inhibitory effect is reversed by antibody against ADAMTS13 TSP1 domains 5-7. Truncated ADAMTS13 lacking the C-terminal TSP1 domain failed to stimulate angiogenesis. Co-immunoprecipitation demonstrated that ADAMTS13 binds VEGF via its TSP1 domain.\",\n      \"method\": \"Matrigel tube formation assay, proliferation counting assay, Boyden chamber migration assay, co-immunoprecipitation, domain truncation analysis\",\n      \"journal\": \"Microvascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cellular assays plus Co-IP for protein interaction, single lab\",\n      \"pmids\": [\"22626948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADAMTS13 modulates atherosclerotic plaque progression through a VWF-dependent mechanism. Triple knockout Adamts13-/-/Vwf-/-/ApoE-/- mice showed complete reversal of exacerbated atherosclerosis seen in Adamts13-/-/ApoE-/- mice, with lesion size, macrophage and neutrophil infiltration, and collagen content reduced to levels seen in Vwf-/-/ApoE-/- mice.\",\n      \"method\": \"Genetic epistasis using triple knockout mice, histological analysis, immunohistochemistry for macrophages and neutrophils, picrosirius red staining for collagen\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in triple knockout mice demonstrating VWF-dependency of ADAMTS13 effect on atherosclerosis\",\n      \"pmids\": [\"24261607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADAMTS13 TSP1 repeats (specifically TSP1 2-8) are required for its pro-angiogenic effects; variants containing TSP1 2-8 repeats increased HUVEC proliferation, migration, and VEGFR2 phosphorylation. ADAMTS13 induces VEGF expression (53% increase at protein level, >6-fold increase in mRNA) within 10 minutes. Anti-VEGF IgG abrogated ADAMTS13-enhanced proliferation, migration, and VEGFR2 phosphorylation.\",\n      \"method\": \"Structure-function analysis with ADAMTS13 truncation variants, ELISA, Western blot for VEGF and phospho-VEGFR2, proliferation and chemotaxis assays, anti-VEGF blocking\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain structure-function combined with signaling readouts and antibody blocking, single lab\",\n      \"pmids\": [\"24950743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In endotoxemia mice, ADAMTS13 plasma activity is decreased within 2 hours of LPS injection. Pretreatment with a neutrophil elastase inhibitor or use of plasminogen-deficient mice prevented the decrease in ADAMTS13 activity, demonstrating that both plasmin and neutrophil elastase coordinately degrade/inactivate ADAMTS13 in endotoxinemia.\",\n      \"method\": \"LPS injection in mice, pharmacological neutrophil elastase inhibitor pretreatment, plasminogen-deficient mouse model, ADAMTS13 activity assays\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological epistasis identifying specific proteases responsible for ADAMTS13 inactivation, single lab\",\n      \"pmids\": [\"18006046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADAMTS13 deficiency impairs post-stroke neovascularization; Adamts13-/- mice showed reduced microvessels, brain capillary perfusion, pericyte coverage, and accelerated BBB breakdown after stroke. These vascular defects were reversed by VWF deficiency or anti-VWF antibody in Adamts13-/- mice. ADAMTS13 deficiency decreased angiopoietin-2 and galectin-3 in brain microvessels; VWF deficiency had the opposite effect. Recombinant ADAMTS13 treatment at 7 days post-stroke increased neovascularization and improved functional recovery.\",\n      \"method\": \"Adamts13-/- and Vwf-/- mouse stroke model, intravital microscopy, histology, recombinant ADAMTS13 treatment, adenovirus angiopoietin-2 overexpression, VEGFR2 antagonist (SU1498)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double knockout rescue), pharmacological intervention, and recombinant protein treatment with multiple orthogonal readouts\",\n      \"pmids\": [\"28428179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADAMTS13 is expressed in human placenta, primarily in trophoblasts and villous core fetal vessel endothelium, and is proteolytically active. Placental ADAMTS13 expression is highest in the first trimester and significantly reduced under hypoxic conditions and in preeclampsia. Recombinant ADAMTS13 stimulates proliferation, migration, invasion, and network formation of trophoblastic cells; knockdown of ADAMTS13 attenuates tube formation in trophoblast cells and extravillous trophoblast outgrowth in placental explants.\",\n      \"method\": \"RT-PCR, immunohistochemistry, Western blot, FRETS-VWF73 activity assay, MTT assay, wound scratch assay, transwell migration assay, tube formation assay, tissue outgrowth assay, ADAMTS13 knockdown\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cellular functional assays with recombinant protein and knockdown, single lab\",\n      \"pmids\": [\"28751574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADAMTS13 deficiency in diabetic mice promotes ventricular arrhythmias through aberrant connexin 43 distribution and increased CaMKII phosphorylation in cardiomyocytes. Thrombospondin-1 (TSP1) promotes CaMKII phosphorylation in cardiomyocytes in a paracrine manner, and ADAMTS13 acts to inhibit TSP1-induced CaMKII activation in vitro.\",\n      \"method\": \"Streptozotocin-induced diabetes in Adamts13-/- mice, dobutamine stress testing, connexin 43 immunolocalization, CaMKII phosphorylation assays, in vitro HL-1 cardiomyocyte TSP1/ADAMTS13 treatment\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo knockout phenotype plus in vitro mechanism, single lab, novel non-VWF function\",\n      \"pmids\": [\"29976618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Recombinant ADAMTS13 treatment reduces NET burden in skin allografts and prolongs allograft survival in mice. Western blot and immunofluorescence microscopy showed NETs in allografts of vehicle-treated but not rhADAMTS13-treated mice 3 days post-surgery, identifying a novel mechanism of ADAMTS13 action in reducing neutrophil extracellular trap formation.\",\n      \"method\": \"Murine skin allograft model, immunofluorescence microscopy, Western blot for NETs, recombinant ADAMTS13 treatment\",\n      \"journal\": \"American journal of transplantation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct detection of mechanism (NET reduction) with functional outcome (allograft survival), single lab\",\n      \"pmids\": [\"31730284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"N-linked glycans of ADAMTS13 regulate its activity. Terminal sialic acid removal from metalloprotease domain glycans decreases ADAMTS13 activity. CUB domain glycan mutations (N1235Q and N1354Q) enhanced activity against both FRETS-VWF73 and VWF under shear, and reduced the CUB-spacer domain interaction (assessed by immunoprecipitation), confirming that CUB domain glycans modulate the closed/open conformational equilibrium. TSP2 domain glycan mutation (N707Q) reduced static but not flow activity.\",\n      \"method\": \"Enzymatic glycan removal, site-directed mutagenesis of N-linked glycan sites, kinetic assays under static and shear conditions, immunoprecipitation of CUB-spacer interaction\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic site mutagenesis with multiple functional readouts and structural interaction assay (immunoprecipitation), single lab but multiple methods\",\n      \"pmids\": [\"28370891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In congenital TTP (Upshaw-Schulman syndrome), ADAMTS13 gene mutations alter ADAMTS13 conformation, with 87.5% of examined patients exhibiting abnormalities of ADAMTS13 conformation. Adult-onset USS is predominantly associated with the p.Arg1060Trp mutation (in 82% of adult-onset patients), suggesting this specific variant preferentially disrupts the spacer-CUB interaction that maintains ADAMTS13 in its folded conformation.\",\n      \"method\": \"ADAMTS13 conformation ELISA, genotyping of 56 USS patients, correlation of genotype with conformation\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conformation assay in patient cohort with genotype correlation, single lab\",\n      \"pmids\": [\"30312976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Anti-cysteine/spacer (CS) domain autoantibodies from iTTP patients can disrupt the spacer-CUB interaction of folded ADAMTS13 (open its conformation). All purified anti-CS fractions from 10/10 patients tested were able to open ADAMTS13, while only 2/4 anti-CUB fractions opened ADAMTS13, establishing the anti-CS antibodies' mechanism of action as disrupting closed conformation.\",\n      \"method\": \"Affinity chromatography purification of anti-CS and anti-CUB autoantibody fractions, ADAMTS13 conformation ELISA\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — purified patient autoantibody fractions with conformation assay, single lab but well-controlled\",\n      \"pmids\": [\"34559219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"siRNA knockdown of endogenous ADAMTS13 in HUVEC reduced proliferation by 21%, abolished scratch wound migration, and decreased tube formation (tube length, size, junction numbers) by ~40%. ADAMTS13 knockdown decreased VEGF protein by 45% and downregulated AKT pathway activity, placing endogenous ADAMTS13 upstream of VEGF/AKT signaling in endothelial angiogenesis.\",\n      \"method\": \"siRNA knockdown of ADAMTS13 in HUVEC, proliferation assay, scratch wound assay, Matrigel tube formation assay, Western blot for VEGF and phospho-AKT\",\n      \"journal\": \"Microvascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific siRNA and multiple functional readouts, pathway placement by western blot, single lab\",\n      \"pmids\": [\"28546076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ADAMTS13 deficiency in APP/PS1 Alzheimer's disease mice caused progressive blood-brain barrier breakdown, reduced vessel density, capillary perfusion, and cerebral blood flow, and accelerated Aβ accumulation. Viral-mediated ADAMTS13 expression in APPPS1 mice with established pathology attenuated BBB disruption, increased microvascular perfusion, increased BBB-mediated Aβ clearance, reduced plaque load, and improved cognitive performance.\",\n      \"method\": \"In vivo multiphoton microscopy, histological analysis, behavioral testing, viral vector ADAMTS13 overexpression in Adamts13-/-/APPPS1 mice\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function with multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"31185010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADAMTS13 deficiency exacerbates diabetic nephropathy through VWF-dependent intrarenal thrombosis. Adamts13-/- diabetic mice had worse kidney function and more intrarenal thrombosis than WT diabetic mice; genetic deletion of VWF in Adamts13-/- diabetic mice improved kidney function and inhibited intrarenal thrombosis, demonstrating that ADAMTS13 protects against diabetic nephropathy by inhibiting VWF-dependent thrombosis.\",\n      \"method\": \"Streptozotocin diabetic mouse model in Adamts13-/-, Vwf-/-, and Adamts13-/-Vwf-/- mice, renal function measurements, immunohistochemistry for thrombosis markers\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (triple genotype rescue experiment) with multiple functional readouts\",\n      \"pmids\": [\"28495930\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADAMTS13 is a constitutively active plasma zinc metalloprotease synthesized primarily by hepatic stellate cells (and also by endothelial cells, platelets, renal tubular cells, and trophoblasts) that cleaves the Tyr1605-Met1606 bond in the VWF A2 domain under fluid shear stress; its proteolytic activity is allosterically regulated by a closed-to-open conformational switch in which autoinhibitory CUB-spacer domain interactions suppress the metalloprotease active site, and binding of VWF's D4 domain (or activating antibodies) to the distal T8-CUB domains opens this conformation to allosterically activate the metalloprotease domain and enable proteolysis of platelet-VWF complexes; beyond VWF cleavage, ADAMTS13 promotes angiogenesis via TSP1 domain-mediated VEGF/VEGFR2 and AKT signaling, inhibits thrombospondin-1-induced CaMKII phosphorylation in cardiomyocytes, reduces NET formation, and attenuates VWF-dependent inflammation in multiple vascular disease models.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADAMTS13 is a plasma zinc metalloprotease that regulates hemostasis by cleaving the Tyr1605-Met1606 bond in the von Willebrand factor (VWF) A2 domain, the physiologic VWF-cleaving activity confirmed by reconstitution with recombinant enzyme [#0, #1]. Cleavage is markedly enhanced when VWF is bound to platelets via GPIbalpha under fluid shear stress, preferentially consuming large, prothrombotic VWF multimers [#4], and the enzyme is released constitutively from the Golgi of endothelial cells to cleave cell-anchored VWF strings [#5]. Catalysis is allosterically controlled by a closed-to-open conformational switch: distal T8-CUB domains autoinhibit the metalloprotease active site through interactions with the proximal MDTCS region, and binding of the VWF D4 domain (or activating antibodies) to T7/T8-CUB relieves this autoinhibition by increasing kcat and opening the occluded active-site cleft [#8, #9, #10, #11]. Substrate engagement is staged through cysteine-rich and spacer exosites that dock VWF, followed by a disintegrin-like domain exosite that allosterically activates the protease, with metalloprotease subsites VR1/VR3 and CUB-domain N-glycans tuning specificity and the conformational equilibrium [#6, #9, #26]. Beyond VWF proteolysis, ADAMTS13 acts through its TSP1 repeats to promote angiogenesis by inducing VEGF expression and VEGFR2/AKT signaling [#18, #20, #29], and protects vascular beds in a VWF-dependent manner across atherosclerosis, diabetic nephropathy, and stroke models [#19, #31, #22]. Mutations in ADAMTS13 that impair secretion, catalysis, or the spacer-CUB conformational interaction cause congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome), and patient autoantibodies against the cysteine/spacer region open the closed conformation in acquired TTP [#2, #27, #28].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing the primary sequence and modular domain architecture defined ADAMTS13 as a multidomain reprolysin-type zinc metalloprotease and predicted zymogen activation, framing all subsequent structure-function work.\",\n      \"evidence\": \"cDNA cloning, Northern blotting, and domain architecture analysis\",\n      \"pmids\": [\"11557746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic substrate not yet demonstrated\", \"Mode of zymogen activation only inferred from furin site\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Reconstitution with recombinant protein answered whether ADAMTS13 is itself the plasma VWF-cleaving protease, confirming identity and that TTP autoantibodies inhibit this activity.\",\n      \"evidence\": \"Recombinant ADAMTS13 in HEK293 cells, VWF multimer degradation assay, inhibition by TTP plasma\",\n      \"pmids\": [\"12393399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Scissile bond and physiologic activation conditions not yet defined\", \"Cellular source in vivo unaddressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mutagenesis of congenital TTP alleles distinguished two disease mechanisms—impaired secretion versus reduced catalytic activity—linking specific variants to loss of function.\",\n      \"evidence\": \"Expression of mutant ADAMTS13 in HeLa cells with secretion and activity readouts\",\n      \"pmids\": [\"12181489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational basis of dysfunction not yet known\", \"Did not address acquired/autoantibody-mediated disease\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying hepatic stellate cells (and endothelial cells/platelets) as cellular sources answered where active ADAMTS13 originates, beyond the liver as an organ.\",\n      \"evidence\": \"In situ hybridization, cell fractionation with activity assays, RT-PCR, platelet lysate activity assays\",\n      \"pmids\": [\"15806136\", \"16176307\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each source to plasma pool unquantified\", \"Regulation of cell-type-specific expression unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating shear- and platelet-GPIbalpha-dependent enhancement of cleavage explained how ADAMTS13 selectively trims the largest, most thrombogenic VWF multimers under physiologic flow.\",\n      \"evidence\": \"Cone-plate viscometer shear assay with anti-GPIbalpha blocking and multimeric gel analysis\",\n      \"pmids\": [\"17901248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of shear-induced substrate exposure not resolved here\", \"Enzyme conformational change not yet linked\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapping the VWF A2 N1574 glycan as a modulator of susceptibility connected substrate glycosylation (and ABO blood group) to cleavage efficiency.\",\n      \"evidence\": \"PNGase F digestion, lectin analysis, recombinant VWF-A2 mutagenesis, binding and proteolysis assays\",\n      \"pmids\": [\"17975018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which glycan shields the scissile site not structurally defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Kinetic and thermodynamic dissection identified VWF A2 'hot spot' residues and ionizable catalytic groups, and proposed a C-shaped enzyme conformation needed to orient the scissile bond.\",\n      \"evidence\": \"FRETS kinetic assays across pH/temperature, Co2+ substitution, product inhibition, molecular modeling\",\n      \"pmids\": [\"18502798\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Computational C-shape model not structurally validated at the time\", \"Single-lab kinetic interpretation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Live-cell imaging established that endothelial ADAMTS13 is secreted constitutively via the Golgi and cleaves cell-anchored VWF strings, defining a local surveillance mechanism distinct from VWF storage.\",\n      \"evidence\": \"Live-cell HUVEC imaging, domain-specific blocking antibodies, VWF string cleavage assay\",\n      \"pmids\": [\"19822897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of endothelial vs plasma enzyme to string cleavage unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Subsite mutagenesis localized determinants of catalytic efficiency (VR1) and P1' specificity (VR3) within the metalloprotease domain, refining the active-site model.\",\n      \"evidence\": \"Domain swapping with ADAMTS1/2, site-directed mutagenesis, kinetics with VWF115\",\n      \"pmids\": [\"20647566\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address distal-domain allosteric control of these subsites\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"SAXS plus truncation kinetics revealed distal T8-CUB autoinhibition relieved by VWF D4 binding, establishing substrate-induced allosteric activation as the core regulatory logic.\",\n      \"evidence\": \"Kinetic assays with truncated variants, SAXS, monoclonal antibody domain blocking\",\n      \"pmids\": [\"25512528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of closed conformation not yet available\", \"Precise distal contact residues unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A crystal structure of the metalloprotease-to-spacer region captured the latent occluded active site and ordered the exosite engagement steps, showing VWF serves as both cofactor and substrate; complementary phylogenetic deletion work pinpointed T7/T8 as the essential allosteric switches.\",\n      \"evidence\": \"X-ray crystallography with exosite mutagenesis; domain deletion across 20 species with shear-dependent cleavage assays\",\n      \"pmids\": [\"31439947\", \"30700419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length closed conformation structure still lacking\", \"T3-T6 function (dispensable here) unexplained\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Kinetic dissection of antibody-induced activation showed the open conformation increases kcat without changing Km, localizing the allosteric effect to the metalloprotease active site rather than exosite exposure.\",\n      \"evidence\": \"Km/kcat kinetics, conformation ELISA, anti-spacer and anti-CUB1 monoclonal antibodies\",\n      \"pmids\": [\"32196558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiologic trigger of the cryptic-epitope exposure in vivo not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Systematic N-glycan mutagenesis showed CUB-domain glycans modulate the CUB-spacer interaction and thus the closed/open equilibrium, linking glycosylation directly to conformational regulation.\",\n      \"evidence\": \"Enzymatic glycan removal, site-directed glycan-site mutagenesis, static/shear kinetics, immunoprecipitation of CUB-spacer interaction\",\n      \"pmids\": [\"28370891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo regulation of glycan occupancy not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Conformation profiling of congenital and acquired TTP established that disease-causing mutations and anti-CS autoantibodies act by disrupting the spacer-CUB interaction that keeps ADAMTS13 folded.\",\n      \"evidence\": \"Conformation ELISA with USS genotyping; affinity-purified anti-CS/anti-CUB autoantibody fractions\",\n      \"pmids\": [\"30312976\", \"34559219\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab conformation assay\", \"Causal link from open conformation to clinical phenotype not directly demonstrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Cellular and Co-IP studies revealed a VWF-independent role: ADAMTS13 TSP1 repeats bind VEGF and promote endothelial proliferation, migration, and tube formation.\",\n      \"evidence\": \"Matrigel/Boyden/proliferation assays, co-immunoprecipitation, domain truncation; receptor-mediated endocytosis by mannose receptor on dendritic cells\",\n      \"pmids\": [\"22626948\", \"22289891\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pro- vs anti-angiogenic effects context-dependent and unreconciled\", \"In vivo relevance of TSP1-VEGF binding not shown here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Loss- and gain-of-function studies placed endogenous ADAMTS13 upstream of VEGF/VEGFR2/AKT signaling and defined its protective vascular roles via VWF-dependent epistasis in stroke, diabetic nephropathy, and atherosclerosis.\",\n      \"evidence\": \"siRNA knockdown in HUVEC with VEGF/AKT/VEGFR2 readouts; Adamts13-/-/Vwf-/- double/triple knockout mouse epistasis in stroke, nephropathy, and atherosclerosis models\",\n      \"pmids\": [\"28546076\", \"24950743\", \"28428179\", \"28495930\", \"24261607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether vascular protection requires proteolytic activity or TSP1-mediated signaling not always separated\", \"Cell-of-origin of the relevant ADAMTS13 in vivo unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Studies in placenta, cardiomyocytes, Alzheimer's models, and allografts extended ADAMTS13 function to trophoblast invasion, inhibition of TSP1-induced CaMKII signaling, blood-brain barrier maintenance/Abeta clearance, and reduction of NET formation.\",\n      \"evidence\": \"Knockdown/recombinant protein in trophoblasts; Adamts13-/- diabetic heart and APPPS1 brain models with viral rescue; murine skin allograft NET imaging\",\n      \"pmids\": [\"28751574\", \"29976618\", \"31185010\", \"31730284\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular substrates/partners in these tissues largely undefined\", \"Single-lab models for each novel function\", \"Dependence on metalloprotease activity vs TSP1 signaling not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the physiologic open-conformation trigger, glycosylation state, and tissue-specific non-VWF functions are integrated and regulated in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No full-length closed-conformation structure\", \"Substrates for non-VWF/TSP1-mediated functions unidentified\", \"Endogenous activators of the conformational switch in vivo undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4, 5, 6, 9]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 12]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 9, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 5, 13]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [1, 4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 27, 28]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [20, 24, 29]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"VWF\", \"GP1BA\", \"VEGFA\", \"THBS1\", \"MRC1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}